HKeyBio
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A Chinese biotech developing monoclonal antibody therapies for oncology and immunology indications.
OncologyImmunology
Technology Platform
Utilizes hybridoma and phage display platforms for therapeutic monoclonal antibody discovery and subsequent engineering for development.
Opportunities
Addressing specific patient subpopulations or novel antibody mechanisms within the large oncology and immunology markets.
Risk Factors
High risk of pipeline attrition during preclinical and clinical development, and potential difficulty in securing funding or partnerships without standout data.
Competitive Landscape
Enters a highly saturated global market for therapeutic antibodies, competing with countless other biotechs on scientific merit and development speed.